Quick Answer
Viking Therapeutics, Inc. reported Diluted EPS of $3.19 per share (loss) for fiscal year 2025.
Viking Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.19 | -215.8% |
| 2024 | -$1.01 | -11.0% |
| 2023 | -$0.91 | -1.1% |
| 2022 | -$0.90 | -26.8% |
| 2021 | -$0.71 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.81 | -268.2% | -39.7% |
| June 30, 2025 | -$0.58 | -190.0% | -41.5% |
| March 31, 2025 | -$0.41 | -57.7% | -86.4% |
| September 30, 2024 | -$0.22 | +4.3% | -10.0% |
| June 30, 2024 | -$0.20 | -5.3% | +23.1% |
| March 31, 2024 | -$0.26 | -4.0% | -13.0% |
| September 30, 2023 | -$0.23 | -9.5% | -21.1% |
| June 30, 2023 | -$0.19 | +17.4% | +24.0% |
- Viking Therapeutics, Inc. showed a decrease of -215.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Viking Therapeutics, Inc.’s diluted eps has declined by 349.3% (from $0.71 per share (loss) to $3.19 per share (loss)).
- The most recent figure is from Viking Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: